Collaboration - January 29, 2020
AroCell enters collaboration with the University Hospital of Pisa
AroCell announces a collaboration with the University Hospital of Pisa, to evaluate the AroCell TK 210 ELISA for Thymidine Kinase 1 (TK1) as a prognostic biomarker in subjects with liver cancer. The aim of the study is to determine the prognostic value of TK1 in combination with imaging techniques to improve prognoses and monitoring in […]
Collaboration - October 16, 2019
AroCell collaborates with Tampere University Hospital
The purpose of the collaboration is to evaluate AroCell’s TK 210 ELISA for Thymidine Kinase 1 (TK1) as a prognostic biomarker in subjects with prostate cancer. In the study TK1 protein levels will be assayed in serum samples collected from subjects with newly diagnosed prostate cancer and compared with the extent and speed of disease […]
Listing - June 22, 2016
AroCell apply for listing on Nasdaq
The Board of Directors of AroCell AB have decided to apply for listing of the company shares to trading on the Nasdaq First North exchange, and thereby change market for share listing. The change of market listing is planned to take place at the turn of the month June/July 2016, and the first date for […]
